MONITOR
( DrugBank: - / KEGG DRUG: - )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
| 11 | Myasthenia gravis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 81 | Congenital adrenal hyperplasia | 1 |
| 129 | Acute encephalopathy with biphasic seizures and late reduced diffusion | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 786 / Drugs : 550 - (DrugBank : 182) / Drug target genes : 170 - Drug target pathways : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
11. Myasthenia gravis
Clinical trials : 439 / Drugs : 223 - (DrugBank : 73) / Drug target genes : 50 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
81. Congenital adrenal hyperplasia
Clinical trials : 102 / Drugs : 72 - (DrugBank : 18) / Drug target genes : 14 - Drug target pathways : 71
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
129. Acute encephalopathy with biphasic seizures and late reduced diffusion
Clinical trial : 1 / Drug : 1 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|